by MM360 Staff | Jun 10, 2021 | Featured News, Myeloma News
The post NICE issues draft ‘no’ on first quadruplet combination for England and Wales appeared first on Myeloma UK.
by MM360 Staff | Jun 10, 2021 | Featured News, Myeloma News
The Blood Cancer UK Vaccine Research Collaborative has announced funding for nine research projects, worth £800K in total, that will look at covid vaccine effectiveness in people with blood cancer. Early data suggests that the coronavirus vaccines may not work as well...
by MM360 Staff | Jun 10, 2021 | Uncategorized
Adding Darzalex (daratumumab) to standard regimens for adults with relapsed or refractory multiple myeloma resulted in higher rates of deep and durable responses, according to exploratory analyses of two Phase 3 trials. These findings, from the ongoing POLLUX...
by MM360 Staff | Jun 10, 2021 | Uncategorized
Heidelberg Pharma has been cleared in the U.S. to begin a clinical trial testing its investigational therapy HDP-101 for the treatment of multiple myeloma. The U.S. Food and Drug Administration (FDA) allowed the start of a Phase 1/2a trial following the submission of...
by MM360 Staff | Jun 10, 2021 | Uncategorized
Using an under-the-skin formulation of Velcade (bortezomib), in combination with Farydak (panobinostat) and oral dexamethasone, leads to a better safety profile in people with relapsed or refractory (resistant) multiple myeloma than does the therapy’s original...
